| Assay Prediction |
Pathology |
Clinical Features |
| Tissue of Origin |
Veridex |
Histology |
IHC |
Age/Sex |
Sites of Metastasis |
Response to Treatment |
Survival (mo) |
| Sarcoma |
Ovarian |
PD carcinoma |
vimentin+, NSE+, synaptophysin+, CD117+, HMB45-, LCA-, chromogranin-, actin-, desmin-, Pan CK-, EMA-, S100- |
40/F |
abdomen, pelvis, liver |
PD |
9 |
| Sarcoma |
Other |
Adenocarcinoma |
None |
56/M |
abdomen, liver |
SD |
24 |
| Sarcoma |
Other |
PD carcinoma |
CK7+, EMA+, CK20-, TTF1-, PLAP- |
61/M |
lung, lymph nodes |
PD |
12 |
| Sarcoma |
Other |
PD carcinoma |
AE1/AE3+, CK20+, NSE+, CK7-, CD30-, desmin-, synaptophysin-, EMA- |
35/M |
lung, liver, lymph nodes |
PR |
6 |
| Sarcoma |
Other |
PD carcinoma |
CK+, S100-, HMB45- |
86/F |
pericardial effusion, adrenal gland, liver |
SD |
5 |
| Sarcoma |
Unsuccessful |
Adenocarcinoma |
None |
65/M |
liver |
SD |
9 |
|
